These findings reveal a new role for metformin in promoting immune antitumorigenic function through NK cell-mediated cytotoxicity and CXCL1 downregulation in HNSCC, informing future immunomodulating therapies in this context. Here, CXCL1 is linked to head and neck squamous cell carcinoma.